BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 34663543)

  • 21. Mutational Analysis of 472 Urothelial Carcinoma Across Grades and Anatomic Sites.
    Nassar AH; Umeton R; Kim J; Lundgren K; Harshman L; Van Allen EM; Preston M; Dong F; Bellmunt J; Mouw KW; Choueiri TK; Sonpavde G; Kwiatkowski DJ
    Clin Cancer Res; 2019 Apr; 25(8):2458-2470. PubMed ID: 30593515
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Genomic profiling of Chinese patients with urothelial carcinoma.
    Yang B; Zhao X; Wan C; Ma X; Niu S; Guo A; Wang J; Wang J; Sun D; Jiao S
    BMC Cancer; 2021 Feb; 21(1):162. PubMed ID: 33588785
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinicopathological Features of FGFR3 - Mutated Upper Tract Urothelial Carcinoma: A Genomic Database Analysis.
    Rizzo A; Mollica V; Santoni M; Massari F
    Clin Genitourin Cancer; 2022 Oct; 20(5):482-487. PubMed ID: 35858936
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Diagnostic value of a comprehensive, urothelial carcinoma-specific next-generation sequencing panel in urine cytology and bladder tumor specimens.
    Sun T; Hutchinson L; Tomaszewicz K; Caporelli ML; Meng X; McCauley K; Fischer AH; Cosar EF; Cornejo KM
    Cancer Cytopathol; 2021 Jul; 129(7):537-547. PubMed ID: 33539671
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Feasibility and tissue concordance of genomic sequencing of urinary cytology in upper tract urothelial carcinoma.
    Katims AB; Gaffney C; Firouzi S; Yip W; Aulitzky A; Pietzak EJ; Donat SM; Bochner BH; Donahue TF; Herr HW; Dalbagni G; Al-Ahmadie H; Kim K; Solit DB; Lin O; Coleman JA
    Urol Oncol; 2023 Oct; 41(10):433.e19-433.e24. PubMed ID: 37640571
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The clinicopathological characteristics of muscle-invasive bladder recurrence in upper tract urothelial carcinoma.
    Shigeta K; Matsumoto K; Ogihara K; Murakami T; Anno T; Umeda K; Izawa M; Baba Y; Sanjo T; Shojo K; Tanaka N; Takeda T; Kosaka T; Mizuno R; Mikami S; Kikuchi E; Oya M
    Cancer Sci; 2021 Mar; 112(3):1084-1094. PubMed ID: 33368857
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Molecular intricacies of upper tract urothelial carcinoma and their relevance for therapy considerations.
    Berndl F; Hassler MR
    Curr Opin Urol; 2022 Jan; 32(1):48-53. PubMed ID: 34772864
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evaluation of molecular signatures in the urinary bladder and upper tract urothelial carcinomas: a prospective controlled clinical study.
    Dawood EE; Awadalla A; Hashem A; Shokeir AA; Abdel-Aziz AF
    J Egypt Natl Canc Inst; 2022 Nov; 34(1):47. PubMed ID: 36372809
    [TBL] [Abstract][Full Text] [Related]  

  • 29. TERT promoter mutations are associated with distant metastases in upper tract urothelial carcinomas and serve as urinary biomarkers detected by a sensitive castPCR.
    Wang K; Liu T; Ge N; Liu L; Yuan X; Liu J; Kong F; Wang C; Ren H; Yan K; Hu S; Xu Z; Björkholm M; Fan Y; Zhao S; Liu C; Xu D
    Oncotarget; 2014 Dec; 5(23):12428-39. PubMed ID: 25474136
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical utility and concordance of upper urinary tract cytology and biopsy in predicting clinicopathological features of upper urinary tract urothelial carcinoma.
    Simon CT; Skala SL; Weizer AZ; Ambani SN; Chinnaiyan AM; Palapattu G; Hafez K; Magers MJ; Kaffenberger SD; Spratt DE; Montgomery JS; Morgan TM; Udager AM; Lew M; Mehra R
    Hum Pathol; 2019 Apr; 86():76-84. PubMed ID: 30537495
    [TBL] [Abstract][Full Text] [Related]  

  • 31. ANXA10 Expression Is Inversely Associated with Tumor Stage, Grade, and TP53 Expression in Upper and Lower Urothelial Carcinoma.
    Kobayashi G; Hayashi T; Sentani K; Ikeda K; Babasaki T; Shigematsu Y; Sekino Y; Uraoka N; Teishima J; Matsubara A; Hinata N; Oue N
    Pathobiology; 2023; 90(2):94-103. PubMed ID: 35780773
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Upper tract urothelial carcinoma has a luminal-papillary T-cell depleted contexture and activated FGFR3 signaling.
    Robinson BD; Vlachostergios PJ; Bhinder B; Liu W; Li K; Moss TJ; Bareja R; Park K; Tavassoli P; Cyrta J; Tagawa ST; Nanus DM; Beltran H; Molina AM; Khani F; Miguel Mosquera J; Xylinas E; Shariat SF; Scherr DS; Rubin MA; Lerner SP; Matin SF; Elemento O; Faltas BM
    Nat Commun; 2019 Jul; 10(1):2977. PubMed ID: 31278255
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Molecular Characterization of Urothelial Carcinoma of the Bladder and Upper Urinary Tract.
    Lee JY; Kim K; Sung HH; Jeon HG; Jeong BC; Seo SI; Jeon SS; Lee HM; Choi HY; Kwon GY; Kim KM; Lee J; Lim HY; Park SH
    Transl Oncol; 2018 Feb; 11(1):37-42. PubMed ID: 29161613
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Characterization of metastatic urothelial carcinoma via comprehensive genomic profiling of circulating tumor DNA.
    Agarwal N; Pal SK; Hahn AW; Nussenzveig RH; Pond GR; Gupta SV; Wang J; Bilen MA; Naik G; Ghatalia P; Hoimes CJ; Gopalakrishnan D; Barata PC; Drakaki A; Faltas BM; Kiedrowski LA; Lanman RB; Nagy RJ; Vogelzang NJ; Boucher KM; Vaishampayan UN; Sonpavde G; Grivas P
    Cancer; 2018 May; 124(10):2115-2124. PubMed ID: 29517810
    [TBL] [Abstract][Full Text] [Related]  

  • 35. IGFBP-5 overexpression as a poor prognostic factor in patients with urothelial carcinomas of upper urinary tracts and urinary bladder.
    Liang PI; Wang YH; Wu TF; Wu WR; Liao AC; Shen KH; Hsing CH; Shiue YL; Huang HY; Hsu HP; Chen LT; Lin CY; Tai C; Wu JY; Li CF
    J Clin Pathol; 2013 Jul; 66(7):573-82. PubMed ID: 23539739
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Genetic polymorphisms on 8q24.1 and 4p16.3 are not linked with urothelial carcinoma of the bladder in contrast to their association with aggressive upper urinary tract tumours.
    Yates DR; Rouprêt M; Drouin SJ; Audouin M; Cancel-Tassin G; Comperat E; Bitker MO; Cussenot O
    World J Urol; 2013 Feb; 31(1):53-9. PubMed ID: 23053209
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Perioperative circulating tumor DNA enables the identification of patients with poor prognosis in upper tract urothelial carcinoma.
    Nakano K; Koh Y; Yamamichi G; Yumiba S; Tomiyama E; Matsushita M; Hayashi Y; Wang C; Ishizuya Y; Yamamoto Y; Kato T; Hatano K; Kawashima A; Ujike T; Fujita K; Kiyotani K; Katayama K; Yamaguchi R; Imoto S; Imamura R; Nonomura N; Uemura M
    Cancer Sci; 2022 May; 113(5):1830-1842. PubMed ID: 35293110
    [TBL] [Abstract][Full Text] [Related]  

  • 38. European Association of Urology Guidelines on Upper Urinary Tract Urothelial Cell Carcinoma: 2015 Update.
    Rouprêt M; Babjuk M; Compérat E; Zigeuner R; Sylvester RJ; Burger M; Cowan NC; Böhle A; Van Rhijn BW; Kaasinen E; Palou J; Shariat SF
    Eur Urol; 2015 Nov; 68(5):868-79. PubMed ID: 26188393
    [TBL] [Abstract][Full Text] [Related]  

  • 39. FGF7 Over Expression is an Independent Prognosticator in Patients with Urothelial Carcinoma of the Upper Urinary Tract and Bladder.
    Fan EW; Li CC; Wu WJ; Huang CN; Li WM; Ke HL; Yeh HC; Wu TF; Liang PI; Ma LJ; Li CF
    J Urol; 2015 Jul; 194(1):223-9. PubMed ID: 25623741
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Frequency of next-generation sequencing, prevalence of targetable mutations and response to targeted therapies amongst patients with metastatic urothelial cancer in Ireland: a multi-centre retrospective study of real-world data.
    Ronan K; Jordan E; Leonard C; McDermott R
    Ir J Med Sci; 2024 Jun; 193(3):1155-1161. PubMed ID: 37947995
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.